(RTTNews) - Viatris (VTRS) said Wednesday that the U.S. District Court for the District of Kansas ruled, in substantial part, in Mylan's favor on the company's summary judgment motion in the class ...

Sen. Patty Murray (D-WA) on Tuesday sent a letter to Mylan CEO Heather Bresch seeking more details, including e-mail communications, on the ways that Mylan attempted to keep Teva’s generic EpiPen from ...

WASHINGTON – Mylan, the embattled drug company whose price hikes of an anti-allergy product sparked calls for a government investigation and a congressional hearing has announced plans to broaden ...

* Mylan says authorized generic, which will reach pharmacies starting next week, has same drug formulation and device functionality as Epipen auto-injector Sign up here. * Authorized generic for ...

Three EpiPen purchasers have filed a class-action lawsuit against Mylan claiming the drug company engaged in an illegal organized scheme to systematically increase EpiPen prices by 574 percent, ...

CVS Health, which owns more than 9,600 retail pharmacies and 1,100 walk-in clinics, will offer a lower-cost generic version of the Adrenaclick epinephrine auto-injector, targeting Mylan after the ...

If Mylan CEO Heather Bresch was hoping for a quiet day Tuesday as she prepared to face a Congressional committee, she was out of luck. Bresch, under fire for price hikes that have left the cost of ...

Drugmaker Mylan announced on Thursday that it will pay $465 million to settle claims relating to the classification of EpiPen auto-injectors and EpiPen Jr. auto-injectors because of allegations of a ...

The U.S. Food and Drug Administration is alerting consumers to Meridian Medical Technologies' voluntary recall of 13 lots of Mylan's EpiPen and EpiPen Jr (epinephrine injection) Auto-Injector products ...

State Medicaid and the State Health Plan will each receive $4. 2 million from an $11 million settlement North Carolina has ...

Mylan and its EpiPen manufacturing partner Pfizer have had trouble keeping up with demand. That's not good news as the key back-to-school season nears. Except, perhaps, for Novartis' Sandoz unit and ...